$DBTX News
Last published 3y ago
- 3y agoDBTXDMSOVOZYNEMoore Kuehn Encourages SOVO, DBTX, DM and ZYNE Investors to Contact Law FirmGlobeNewswireNEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoCTGDBTXKLRZYNEMoore Kuehn Encourages CTG, KLR, ZYNE, and DBTX Investors to Contact Law FirmGlobeNewswireNEW YORK, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoAMEDDBTXRETASURFMoore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law FirmGlobeNewswireNEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoARCEAVIDCPRIDBTXMoore Kuehn Encourages DBTX, AVID, CPRI, and ARCE Investors to Contact Law FirmGlobeNewswireNEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoDBTXDecibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate UpdateGlobeNewswire- Activated CHORDTM clinical trial sites in U.S., U.K. and Spain and commenced patient screening activities; anticipate dosing first patient in the Phase 1/2 clinical trial in the second half of 2023 - - Received
- 3y agoDBTXDBTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Decibel Therapeutics to Regeneron PharmaceuticalsGlobeNewswireMONSEY, N.Y., Aug. 09, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the $4.00 per share in cash, plus a contingent value right ("CVR") for up to $3.50 per share in
- 3y agoDBTXREGNRegeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss ProgramsGlobeNewswireProposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel's lead investigational gene therapy
- 3y agoDBTXDecibel Therapeutics to Participate in the Upcoming Jefferies Healthcare ConferenceGlobeNewswireBOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and
- 3y agoDBTXDecibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual MeetingGlobeNewswireBOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and
- 3y agoDBTXDecibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy SummitGlobeNewswireBOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and
- 3y agoDBTXDecibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate UpdateGlobeNewswire- Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, DB-OTO - - Announced approval from the U.K. MHRA and Spanish AEMPS for CTAs for CHORD to expand the
- 3y agoDBTXDecibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTOGlobeNewswireBOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and
- 3y agoDBTXDecibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual MeetingGlobeNewswireBOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and
- 3y agoDBTXDecibel Therapeutics Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTOGlobeNewswire- Decibel intends to initiate a Phase 1/2 clinical trial of DB-OTO in patients with congenital hearing loss caused my mutations of the otoferlin gene in the first half of 2023 - - There are currently no approved
- 3y agoDBTXDecibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease DaysGlobeNewswireBOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and
- 3y agoDBTXDecibel Therapeutics Appoints Matthew Kapusta to its Board of DirectorsGlobeNewswireBOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and
- 3y agoDBTXDecibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate UpdateGlobeNewswire- Received clearance from US FDA for IND and from UK MHRA for CTA to initiate CHORD™, a global Phase 1/2 dose escalation clinical trial of DB-OTO in pediatric patients - - Plan to initiate the
- 3y agoDBTXDecibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma ConferenceGlobeNewswireBOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and
- 3y agoDBTXDecibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter MeetingGlobeNewswireBOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and
- 3y agoDBTXDecibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTOGlobeNewswireThe CTA authorization for DB-OTO provides approval for the Company to expand its planned Phase 1/2 clinical trial to the U.K. in patients two years of age and younger One-time administration of DB-OTO has resulted in
- 4y agoDBTXDecibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate UpdateGlobeNewswire- Received FDA Clearance of IND Application for DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss - - Announced Submission of CTAs for DB-OTO in the
- 4y agoDBTXDecibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTOGlobeNewswireBOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing
- 4y agoDBTXDecibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing LossGlobeNewswireThe IND for DB-OTO provides clearance for the Company to initiate a pediatric Phase 1/2 clinical trial in the U.S. in children and infants, and is part of an international regulatory strategy for clinical
- 4y agoDBTXDecibel Therapeutics Appoints Kevin F. McLaughlin to its Board of DirectorsGlobeNewswireBOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and
- 4y agoDBTXDecibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine SummitGlobeNewswireBOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Lau
- 4y agoDBTXDecibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTOGlobeNewswireBOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the subm
- 4y agoDBTXDecibel Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laur
- 4y agoDBTXDecibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate UpdateGlobeNewswire- Announced positive data from interim analysis of Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy; data support continued development of DB-020 as a potential therapy to protect against hearing loss in patients receiving c
- 4y agoDBTXDecibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin ChemotherapyGlobeNewswire- 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear – - Data support continued development of DB-020 as a potential therapy to protect against hearing loss in patient
- 4y agoDBTXDecibel Therapeutics to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireBOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that John
- 4y agoDBTXDecibel Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireBOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laure
- 4y agoDBTXDecibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate UpdateGlobeNewswire- Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of Phase 1b trial of DB-020 for cisplatin-induced hearing loss and product candidate selection for AAV.103 program –
- 4y agoDBTXDecibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual MeetingGlobeNewswireBOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it wi
- 4y agoDBTXDecibel Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Lau
- 4y agoDBTXDecibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate UpdateGlobeNewswire- Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and results from interim analysis from Phase 1b trial of DB-020 for cisplatin-induced hearing loss - - Research term extended under strategic collaboration with Regene
- 4y agoDBTXDecibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireBOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laur
- 4y agoDBTXDecibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Across Gene Therapy PipelineGlobeNewswire- Podium presentation at Association for Research in Otolaryngology Annual MidWinter Meeting highlighting DB-OTO dose-ranging studies with expression analysis, functional recovery and tolerability data - - Podium presentation and posters with new prec
- 4y agoDBTXDecibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) MeetingGlobeNewswireBOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it w
- 4y agoDBTXDecibel Therapeutics to Present at the H.C. Wainwright BioConnect ConferenceGlobeNewswireBOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laur
- 4y agoDBTXDecibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from BoardGlobeNewswireBOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appoi
- 4y agoDBTXDecibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing LossGlobeNewswireCollaboration gene therapy product candidate, DB-OTO, on track to enter clinical testing in 2022; two additional gene therapy programs for congenital, monogenic forms of hearing loss in development under the collaboration Decibel to receive $10 million
- 5y agoDBTXDecibel Therapeutics Reports Third Quarter 2021 Financial Results and Corporate UpdateGlobeNewswire- Received Orphan Drug and Rare Pediatric Disease designations for DB-OTO for the treatment of otoferlin-related congenital hearing loss – - On track for key 2022 milestones including submission of IND and/or CTA for DB-OTO and interim analysis of D
- 5y agoDBTXDecibel Therapeutics to Present at the Barclays Gene Editing & Gene Therapy SummitGlobeNewswireBOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced its parti
- 5y agoDBTXDecibel Therapeutics to Present at the Jefferies Gene Therapy/Editing SummitGlobeNewswireBOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laur
- 5y agoDBTXDecibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear DamageGlobeNewswireBOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that fin
- 5y agoDBTXDecibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing LossGlobeNewswireBOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the
- 5y agoDBTXDecibel Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireBOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the
- 5y agoDBTXDecibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate SecretaryGlobeNewswireBOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appoi
- 5y agoDBTXDecibel Therapeutics Reports Second Quarter 2021 Financial Results and Corporate UpdateGlobeNewswire- Bolstered Board of Directors and Scientific Advisory Board with key appointments - - On track for anticipated 2022 milestones including submission of IND and/or CTA for DB-OTO and interim analysis of DB-020 Phase 1b trial for cisplatin-induced h
- 5y agoDBTXDecibel Therapeutics Appoints Dr. William H. Carson as Chairman of the Board of DirectorsGlobeNewswireBOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appoi